Wu Liang

Predicting the Pharmacokinetic Characteristics of Edaravone Intravenous Injection and Sublingual Tablet Through Modeling and Simulation.

Yilong Wang, Yongjun Wang, Xingquan Zhao, 2020, Clinical Therapeutics.

Population pharmacokinetics and exposure‐response analysis of tigecycline in patients with hospital‐acquired pneumonia

Han Yan, H. L. Banh, Wu Liang, 2020, British journal of clinical pharmacology.

Impact of CYP2C19 Genotype and Liver Function on Voriconazole Pharmacokinetics in Renal Transplant Recipients

Sheng-Lan Tan, M. Yan, Wu Liang, 2017, Therapeutic drug monitoring.

Population pharmacokinetics of voriconazole and CYP2C19 polymorphisms for optimizing dosing regimens in renal transplant recipients

M. Yan, Wu Liang, P. Xu, 2018, British journal of clinical pharmacology.

Population pharmacokinetic analysis of intravenous busulfan: GSTA1 genotype is not a predictive factor of initial dose in Chinese adult patients undergoing hematopoietic stem cell transplantation

Jiong Hu, Wanhua Yang, Wu Liang, 2019, Cancer Chemotherapy and Pharmacology.

Accurate Prediction of Initial Busulfan Exposure Using a Test Dose With 2‐ and 6‐Hour Blood Sampling in Adult Patients Receiving a Twice‐Daily Intravenous Busulfan‐Based Conditioning Regimen

Jiong Hu, Wanhua Yang, Wu Liang, 2018, Journal of clinical pharmacology.

Population pharmacokinetics, safety and dosing optimization of voriconazole in patients with liver dysfunction: A prospective observational study

Jian-jun Zou, Yongfang Jiang, G. Gong, 2020, British journal of clinical pharmacology.

Population pharmacokinetics, safety and dosing optimization of voriconazole in patients with liver dysfunction: a prospective study

Jian-jun Zou, Yongfang Jiang, M. Zhang, 2020 .